A detailed history of Farther Finance Advisors, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 231 shares of TGTX stock, worth $6,823. This represents 0.0% of its overall portfolio holdings.

Number of Shares
231
Previous 213 8.45%
Holding current value
$6,823
Previous $3.86 Million 39.78%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$17.21 - $25.28 $309 - $455
18 Added 8.45%
231 $5.4 Million
Q2 2024

Jul 31, 2024

BUY
$13.32 - $19.19 $346 - $498
26 Added 13.9%
213 $3.86 Million
Q1 2024

May 13, 2024

BUY
$13.02 - $21.3 $351 - $575
27 Added 16.88%
187 $2.76 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $400 - $1,128
60 Added 60.0%
160 $2.73 Million
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $836 - $2,650
100 New
100 $836,000
Q4 2022

Sep 11, 2023

BUY
$5.01 - $11.83 $475 - $1,123
95 New
95 $1.12 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.